EP1832298A4 - Matrix-type controlled release preparation comprising basic substance or salt thereof, and process for production of the same - Google Patents

Matrix-type controlled release preparation comprising basic substance or salt thereof, and process for production of the same

Info

Publication number: EP1832298A4
Authority: EP; European Patent Office
Prior art keywords: matrix; salt; production; same; controlled release
Prior art date: 2004-12-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP05822550A

Other languages

German (de)

French (fr)

Other versions

EP1832298A1 (en

Inventor

Yosuke Ueki

Satoshi Fujioka

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai R&D Management Co Ltd

Original Assignee

Eisai R&D Management Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-27

Filing date

2005-12-27

Publication date

2012-12-12

2005-12-27 Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd

2007-09-12 Publication of EP1832298A1 publication Critical patent/EP1832298A1/en

2012-12-12 Publication of EP1832298A4 publication Critical patent/EP1832298A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP05822550A 2004-12-27 2005-12-27 Matrix-type controlled release preparation comprising basic substance or salt thereof, and process for production of the same Withdrawn EP1832298A4 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP2004376770		2004-12-27
JP2005110404		2005-04-06
US67548205P	2005-04-28	2005-04-28
JP2005132338		2005-04-28
PCT/JP2005/023853 WO2006070781A1 (en)	2004-12-27	2005-12-27	Matrix-type controlled release preparation comprising basic substance or salt thereof, and process for production of the same

Publications (2)

Publication Number	Publication Date
EP1832298A1 EP1832298A1 (en)	2007-09-12
EP1832298A4 true EP1832298A4 (en)	2012-12-12

Family

ID=36614895

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP05822550A Withdrawn EP1832298A4 (en)	2004-12-27	2005-12-27	Matrix-type controlled release preparation comprising basic substance or salt thereof, and process for production of the same

Country Status (13)

Country	Link
US (2)	US20090208579A1 (en)
EP (1)	EP1832298A4 (en)
JP (1)	JP4999466B2 (en)
KR (1)	KR100904602B1 (en)
CN (1)	CN103550190A (en)
AU (1)	AU2005320609B9 (en)
BR (1)	BRPI0519407A2 (en)
CA (1)	CA2592102C (en)
IL (1)	IL183871A0 (en)
MX (1)	MX2007007835A (en)
NO (1)	NO20073461L (en)
NZ (1)	NZ555901A (en)
WO (1)	WO2006070781A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7619007B2 (en)	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
NZ555693A (en)	2004-12-27	2010-10-29	Eisai R&D Man Co Ltd	Matrix type sustained-release preparation containing donepezil
EP1874282B1 (en)	2005-04-06	2010-09-15	Adamas Pharmaceuticals, Inc.	Methods and compositions for treatment of cns disorders
CN101166543B (en) *	2005-04-28	2014-07-16	卫材R&D管理有限公司	Composition containing anti-dementia drug
MX2008016568A (en) *	2006-07-05	2009-01-19	Teva Pharma	Pharmaceutical compositions of memantine.
WO2008073282A2 (en) *	2006-12-07	2008-06-19	Schering Corporation	Ph sensitive matrix formulation
TWI433674B (en)	2006-12-28	2014-04-11	Infinity Discovery Inc	Cyclopamine analogs
DE102007009242A1 (en) *	2007-02-22	2008-09-18	Evonik Röhm Gmbh	Pellets with enteric-coated matix
EP2134719B1 (en)	2007-03-07	2013-07-17	Infinity Discovery, Inc.	Cyclopamine lactam analogs and methods of use thereof
US7648994B2 (en)	2007-03-07	2010-01-19	Infinity Discovery, Inc.	Heterocyclic cyclopamine analogs and methods of use thereof
CN104059124A (en)	2007-12-27	2014-09-24	无限药品股份有限公司	Methods For Stereoselective Reduction
MX2011006463A (en)	2008-12-19	2011-07-20	Supernus Pharmaceuticals Inc	Method of treatment of aggression.
KR20120003906A (en)	2009-03-27	2012-01-11	교린 세이야꾸 가부시키 가이샤	Matrix sustained-release preparations containing basic additives
CA2769795C (en)	2009-08-05	2020-01-07	Infinity Pharmaceuticals, Inc.	Enzymatic transamination of cyclopamine analogs
JP2011037787A (en) *	2009-08-13	2011-02-24	Kyorin Pharmaceutical Co Ltd	STABLE RELEASE COMPOSITION INDEPENDENT OF pH OF BASIC DRUG
JP2013510180A (en) *	2009-11-06	2013-03-21	インフィニティファーマスーティカルズ、インク．	Oral formulation of hedgehog pathway inhibitor
BR112012013487A2 (en)	2009-12-02	2017-10-03	Adamas Pharmaceuticals Inc	AMANTADINE COMPOSITIONS AND METHODS OF USE
BRPI1005440A2 (en) *	2010-01-26	2016-03-08	Hyundai Pharm Co Ltd	pharmaceutical matrix composition
US20110218216A1 (en) *	2010-01-29	2011-09-08	Kumaravel Vivek	Extended release pharmaceutical composition of donepezil
JP5563841B2 (en) *	2010-02-05	2014-07-30	沢井製薬株式会社	Oral pharmaceutical composition masking unpleasant taste of drug
WO2011102505A1 (en) *	2010-02-22	2011-08-25	第一三共株式会社	Sustained-release solid preparation for oral use
JP5749247B2 (en) *	2010-02-22	2015-07-15	第一三共株式会社	Oral sustained-release solid preparation
EP2366378A1 (en)	2010-03-01	2011-09-21	Dexcel Pharma Technologies Ltd.	Sustained-release donepezil formulations
JP6063377B2 (en)	2010-03-31	2017-01-18	スパーナスファーマシューティカルズインコーポレイテッド	Stabilized formulation of CNS compound
US20110251239A1 (en) *	2010-04-07	2011-10-13	Eisai Inc.	Combination therapy for the treatment of dementia
US20120040008A1 (en) *	2010-08-11	2012-02-16	Ashish Chatterji	Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US9376447B2 (en)	2010-09-14	2016-06-28	Infinity Pharmaceuticals, Inc.	Transfer hydrogenation of cyclopamine analogs
AU2011316565A1 (en)	2010-10-12	2013-05-02	Cerecor Inc.	Antitussive compositions comprising memantine
WO2012053016A1 (en)	2010-10-22	2012-04-26	Cadila Healthcare Limited	Sustained release pharmaceutical compositions of donepezil
WO2013033432A1 (en) *	2011-09-03	2013-03-07	Adipocyte Therapeutics Inc	Methods and compositions for treating type 2 diabetes and related conditions
RU2665372C2 (en)	2012-09-03	2018-08-29	Дайити Санкио Компани, Лимитед	Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
WO2014132215A1 (en) *	2013-02-28	2014-09-04	Lupin Limited	Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
CN105163723A (en) *	2013-02-28	2015-12-16	鲁平有限公司	Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
WO2014204933A1 (en)	2013-06-17	2014-12-24	Adamas Pharmaceuticals, Inc.	Amantadine compositions and methods of use
JP6796638B2 (en)	2015-06-04	2020-12-09	ペレファーム, インク.Pellepharm, Inc.	Topical formulations and their use for the delivery of hedgehog inhibitory compounds
US20170056342A1 (en) *	2015-08-31	2017-03-02	Apotex Technologies Inc.	Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride
KR101938872B1 (en) *	2016-09-30	2019-01-16	주식회사 바이오파마티스	Composition comprising complex for prevention and treatment of dementia and cognitive impairment
JP7023186B2 (en) *	2017-05-29	2022-02-21	第一三共株式会社	Orally disintegrating tablets containing dementia treatment
JP6578459B1 (en) *	2019-02-28	2019-09-18	アピ株式会社	Hard capsule and manufacturing method thereof
KR20210072569A (en) *	2019-12-09	2021-06-17	주식회사 종근당	Complex formulation comprising donepezil and memantine
CN115876900A (en) *	2021-09-28	2023-03-31	江苏正大清江制药有限公司	Method for measuring dissolution amount of bromhexine hydrochloride in clohexine dry suspension
WO2023095183A1 (en) *	2021-11-24	2023-06-01	Jordan University Of Science And Technology	A pharmaceutical composition and a solid dosage form thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0194838A2 (en) *	1985-03-08	1986-09-17	Yamanouchi Pharmaceutical Co. Ltd.	Controlled-release pharmaceutical formulation
US4968508A (en) *	1987-02-27	1990-11-06	Eli Lilly And Company	Sustained release matrix
JPH06199657A (en) *	1992-12-10	1994-07-19	Sumitomo Pharmaceut Co Ltd	Sustained release formulation
JPH0920663A (en) *	1995-07-07	1997-01-21	Teikoku Seiyaku Co Ltd	Sustained release fine granules containing ibudilast and method for producing the same
WO2000018378A1 (en) *	1998-09-25	2000-04-06	Euro-Celtique, S.A.	Sustained release hydromorphone formulations exhibiting bimodal characteristics
EP1086706A1 (en) *	1999-03-31	2001-03-28	Eisai Co., Ltd.	Stabilized compositions containing nootropic drugs
WO2004087116A2 (en) *	2003-03-05	2004-10-14	Osmotica Corp.	Drug combination for motor dysfunction in parkinson's disease
CN1608623A (en) *	2004-11-05	2005-04-27	贵州圣济堂制药有限公司	Enteric coated donepezil hydrochloride tablet and its perpn process
WO2005092336A1 (en) *	2004-03-26	2005-10-06	Eisai R&D Management Co., Ltd.	Controlled-leaching preparation and process for producing the same
CN1709229A (en) *	2005-06-10	2005-12-21	北京阜康仁生物制药科技有限公司	Memantine hydrochloride orally disintegrating tablet and its preparing method
WO2006070930A1 (en) *	2004-12-27	2006-07-06	Eisai R & D Management Co., Ltd.	Method for stabilizing anti-dementia drug
EP1878444A1 (en) *	2005-04-28	2008-01-16	Eisai R&D Management Co., Ltd.	Composition containing antidementia agent

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU187215B (en) *	1983-01-26	1985-11-28	Egyt Gyogyszervegyeszeti Gyar	Method for producing pharmaceutical product of high actor content and prolonged effect
IL72381A (en) *	1983-07-20	1988-03-31	Sanofi Sa	Pharmaceutical composition based on valproic acid
US4892742A (en) *	1985-11-18	1990-01-09	Hoffmann-La Roche Inc.	Controlled release compositions with zero order release
IL81419A0 (en) *	1986-01-30	1987-08-31	Syntex Inc	Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
US4940556A (en) *	1986-01-30	1990-07-10	Syntex (U.S.A.) Inc.	Method of preparing long acting formulation
US4832957A (en) *	1987-12-11	1989-05-23	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
HU202753B (en) *	1986-06-21	1991-04-29	Sandoz Ag	Process for producing retard pharmaceutical compositions containing cetotiphene
CA1308357C (en) *	1987-01-28	1992-10-06	Tohru Chiba	Method for the preparation of a coated solid medicament
US4851232A (en) *	1987-02-13	1989-07-25	Alza Corporation	Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4894239A (en) *	1987-06-02	1990-01-16	Takeda Chemical Industries, Ltd.	Sustained-release preparation and production thereof
US4891223A (en) *	1987-09-03	1990-01-02	Air Products And Chemicals, Inc.	Controlled release delivery coating formulation for bioactive substances
JP2643222B2 (en) *	1988-02-03	1997-08-20	エーザイ株式会社	Multi-layer granules
DE3827214A1 (en) *	1988-08-11	1990-02-15	Roehm Gmbh	RETARDED MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF
JP2514078B2 (en) *	1988-08-22	1996-07-10	エスエス製薬株式会社	Compressed formulation
JP2893191B2 (en) *	1988-11-08	1999-05-17	武田薬品工業株式会社	Controlled release matrix agent
US5202128A (en) *	1989-01-06	1993-04-13	F. H. Faulding & Co. Limited	Sustained release pharmaceutical composition
DE69020758T2 (en) *	1989-03-10	1995-12-07	Yamanouchi Pharma Co Ltd	Coating material that controls drug delivery for long-acting formulations.
NZ233403A (en) *	1989-04-28	1992-09-25	Mcneil Ppc Inc	Simulated capsule-like medicament
US5102668A (en) *	1990-10-05	1992-04-07	Kingaform Technology, Inc.	Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5266331A (en) *	1991-11-27	1993-11-30	Euroceltique, S.A.	Controlled release oxycodone compositions
US5681585A (en) *	1991-12-24	1997-10-28	Euro-Celtique, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
DE4225730C2 (en) *	1992-08-04	2003-04-30	Merz Pharma Gmbh & Co Kgaa	Process for the preparation of solid dosage forms with protracted 2-stage release
KR950007873A (en) *	1993-09-20	1995-04-15	후꾸하라 요시하루	Biologics Sustained-Release Pharmaceutical Formulations
US5500227A (en) *	1993-11-23	1996-03-19	Euro-Celtique, S.A.	Immediate release tablet cores of insoluble drugs having sustained-release coating
US5698224A (en) *	1994-06-27	1997-12-16	Alza Corporation	Tacrine therapy
US5871776A (en) *	1995-01-31	1999-02-16	Mehta; Atul M.	Controlled-release nifedipine
US6083532A (en) *	1995-03-01	2000-07-04	Duramed Pharmaceuticals, Inc.	Sustained release formulation containing three different types of polymers and tablet formed therefrom
AUPN605795A0 (en) *	1995-10-19	1995-11-09	F.H. Faulding & Co. Limited	Analgesic pharmaceutical composition
IT1282650B1 (en) *	1996-02-19	1998-03-31	Jagotec Ag	PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
US5773031A (en) *	1996-02-27	1998-06-30	L. Perrigo Company	Acetaminophen sustained-release formulation
US6245351B1 (en) *	1996-03-07	2001-06-12	Takeda Chemical Industries, Ltd.	Controlled-release composition
DE69734060T2 (en) *	1996-05-24	2006-06-29	Angiotech Pharmaceuticals, Inc., Vancouver	PREPARATIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF THE BODY PASSAGE PATHS
IT1289160B1 (en) *	1997-01-08	1998-09-29	Jagotec Ag	FULLY COATED PHARMACEUTICAL TABLET FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS WHICH PRESENT PROBLEMS OF
DE19707655A1 (en) *	1997-02-26	1998-08-27	Hoechst Ag	Combination preparation for use in dementia
CA2216215A1 (en) *	1997-04-05	1998-10-05	Isa Odidi	Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6210710B1 (en) *	1997-04-28	2001-04-03	Hercules Incorporated	Sustained release polymer blend for pharmaceutical applications
US7008950B1 (en) *	1997-06-05	2006-03-07	Takeda Chemical Industries, Ltd.	Benzofurans as suppressors of neurodegeneration
FR2766708B1 (en) *	1997-07-30	2000-05-05	Galenix Dev	COMPOSITION CONTAINING HYDROXYPROPYLCELLULOSE, HYDROXYPROPYLMETHYLCELLULOSE AND / OR ETHYLCELLULLOSE AS DISINTEGRANTS, AND PROCESS FOR OBTAINING SAME
JP3797764B2 (en) *	1997-10-01	2006-07-19	エーザイ株式会社	Light stabilizing composition
US20040028735A1 (en) *	1997-11-14	2004-02-12	Unchalee Kositprapa	Pharmaceutical formulation
US20030092737A1 (en) *	1997-11-14	2003-05-15	Pierre Maffrand Jean	Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
FR2772615B1 (en) *	1997-12-23	2002-06-14	Lipha	MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
US6251430B1 (en) *	1998-02-04	2001-06-26	Guohua Zhang	Water insoluble polymer based sustained release formulation
US6372254B1 (en) *	1998-04-02	2002-04-16	Impax Pharmaceuticals Inc.	Press coated, pulsatile drug delivery system suitable for oral administration
ES2221370T3 (en) *	1998-04-03	2004-12-16	Egalet A/S	COMPOSITION OF CONTROLLED RELEASE.
US6262081B1 (en) *	1998-07-10	2001-07-17	Dupont Pharmaceuticals Company	Composition for and method of treating neurological disorders
UA73092C2 (en) *	1998-07-17	2005-06-15	Брістол-Майерс Сквібб Компані	Tablets with enteric coating and method for their manufacture
WO2000012135A1 (en) *	1998-08-28	2000-03-09	Eisai Co., Ltd	Medicinal compositions with relieved bitterness, etc.
US6531152B1 (en) *	1998-09-30	2003-03-11	Dexcel Pharma Technologies Ltd.	Immediate release gastrointestinal drug delivery system
CA2347104A1 (en) *	1998-10-26	2000-04-05	Tanabe Seiyaku Co., Ltd.	Sustained-release particles
US6797283B1 (en) *	1998-12-23	2004-09-28	Alza Corporation	Gastric retention dosage form having multiple layers
CN100370990C (en) *	1998-12-24	2008-02-27	詹森药业有限公司	Controlled release galantamine composition
EP1027887B1 (en) *	1999-02-10	2008-08-13	Pfizer Products Inc.	Matrix controlled release device
US6706283B1 (en) *	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
BR0009437A (en) *	1999-03-31	2002-01-15	Janssen Pharmaceutica Nv	Pre-gelatinized starch in a controlled release formulation
US7919119B2 (en) *	1999-05-27	2011-04-05	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US20030124176A1 (en) *	1999-12-16	2003-07-03	Tsung-Min Hsu	Transdermal and topical administration of drugs using basic permeation enhancers
BR0007360A (en) *	1999-12-23	2001-08-14	Johnson & Johnson	Controlled release composition
US6627223B2 (en) *	2000-02-11	2003-09-30	Eurand Pharmaceuticals Ltd.	Timed pulsatile drug delivery systems
WO2001066096A2 (en) *	2000-03-06	2001-09-13	Immune Network Ltd.	Compositions for prevention and treatment of dementia
DE10029201A1 (en) *	2000-06-19	2001-12-20	Basf Ag	Retarded release oral dosage form, obtained by granulating mixture containing active agent and polyvinyl acetate-polyvinyl pyrrolidone mixture below the melting temperature
GB0025208D0 (en) *	2000-10-13	2000-11-29	Euro Celtique Sa	Delayed release pharmaceutical formulations
CA2359812C (en) *	2000-11-20	2004-02-10	The Procter & Gamble Company	Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
SE0004671D0 (en) *	2000-12-15	2000-12-15	Amarin Dev Ab	Pharmaceutical formulation
US6287599B1 (en) *	2000-12-20	2001-09-11	Shire Laboratories, Inc.	Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2350195C (en) *	2000-12-20	2003-06-10	Duchesnay Inc.	Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
US6667070B1 (en) *	2001-02-02	2003-12-23	Advanced Micro Devices, Inc.	Method of in situ monitoring of thickness and composition of deposited films using raman spectroscopy
WO2002066004A1 (en) *	2001-02-23	2002-08-29	Mitsubishi Pharma Corporation	Compositions with controlled drug release
US20040022853A1 (en) *	2001-04-26	2004-02-05	Control Delivery Systems, Inc.	Polymer-based, sustained release drug delivery system
WO2003000235A1 (en) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of dispersions of drugs and neutral polymers
US6673369B2 (en) *	2001-08-29	2004-01-06	Ranbaxy Laboratories Limited	Controlled release formulation
US20050053657A1 (en) *	2001-08-29	2005-03-10	Ashok Rampal	Controlled release formulation of clarithromycin or tinidazol
US20030118649A1 (en) *	2001-10-04	2003-06-26	Jinming Gao	Drug delivery devices and methods
US6592901B2 (en) *	2001-10-15	2003-07-15	Hercules Incorporated	Highly compressible ethylcellulose for tableting
AUPR839001A0 (en) *	2001-10-19	2001-11-15	Eli Lilly And Company	Dosage form, device and methods of treatment
PT1443917E (en) *	2001-11-07	2006-06-30	Synthon Bv	TAMSULOSIN TABLETS
EP1455751A1 (en) *	2001-12-20	2004-09-15	Pharmacia Corporation	Zero-order sustained released dosage forms and method of making the same
US20050142088A1 (en) *	2002-02-07	2005-06-30	Mitsuru Mizuno	Hair growth stimulants, percutaneous preparations and method of stimulating hair growth
HRP20020124A2 (en) *	2002-02-11	2003-10-31	Pliva D D	Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2003070223A1 (en) *	2002-02-21	2003-08-28	Otsuka Pharmaceutical Co., Ltd.	Sustained release preparations and process for producing the same
GB0204772D0 (en) *	2002-02-28	2002-04-17	Phoqus Ltd	Pharmaceutical dosage forms
FR2838647B1 (en) *	2002-04-23	2006-02-17		PROLONGED RELEASE PARTICLES, PROCESS FOR THEIR PREPARATION AND TABLETS CONTAINING SAME
US20040005358A1 (en) *	2002-04-23	2004-01-08	Slugg Peter H.	Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2003103634A1 (en) *	2002-06-07	2003-12-18	Ranbaxy Laboratories Limited	Sustained release oral dosage forms of gabapentin
IL150509A (en) *	2002-07-01	2007-07-04	Joseph Kaspi	Pharmaceutical compositions containing donepezil hydrocholoride
US20050048119A1 (en) *	2002-09-20	2005-03-03	Avinash Nangia	Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
AU2003274353B2 (en) *	2002-10-24	2007-04-05	Merz Pharma Gmbh & Co. Kgaa	Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004050068A1 (en) *	2002-11-29	2004-06-17	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
IL154370A0 (en) *	2003-02-10	2003-09-17	Chemagis Ltd	Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US7439365B2 (en) *	2003-11-17	2008-10-21	Usv, Ltd.	Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil)
EP1607088B1 (en) *	2003-03-17	2019-02-27	Takeda Pharmaceutical Company Limited	Controlled release composition
WO2004108067A2 (en) *	2003-04-03	2004-12-16	Sun Pharmaceutical Industries Limited	Programmed drug delivery system
EP2529730A1 (en) *	2003-06-16	2012-12-05	ANDRX Pharmaceuticals LLC.	Oral sustained-release composition
RU2375048C2 (en) *	2003-07-17	2009-12-10	Д-Р Редди'С Лабораторис Инк.	Pharmacological composition with swelling coating
US20050013863A1 (en) *	2003-07-18	2005-01-20	Depomed, Inc., A Corporation Of The State Of California	Dual drug dosage forms with improved separation of drugs
US20050025829A1 (en) *	2003-07-29	2005-02-03	Kim Cherng-Ju	Controlled drug release tablets
AU2004264316A1 (en) *	2003-08-06	2005-02-24	Alza Corporation	Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US20050136108A1 (en) *	2003-08-22	2005-06-23	Yam Noymi V.	Stepwise delivery of topiramate over prolonged period of time
EP1670442A4 (en) *	2003-09-19	2011-09-14	Penwest Pharmaceuticals Co	Delayed released dosage forms
ATE504288T1 (en) *	2003-09-26	2011-04-15	Alza Corp	OROS PUSH STICK FOR THE CONTROLLED DELIVERY OF ACTIVE INGREDIENTS
EP1523979A1 (en) *	2003-10-13	2005-04-20	Wyeth	Extended release pharmaceutical dosage form
US20050084531A1 (en) *	2003-10-16	2005-04-21	Jatin Desai	Tablet with aqueous-based sustained release coating
US20050129751A1 (en) *	2003-12-16	2005-06-16	Rothenberg Barry E.	Drug delivery compositions and methods
US20050129759A1 (en) *	2003-12-16	2005-06-16	Milan Sojka	Sustained release compositions and controlled delivery method
US20050163843A1 (en) *	2003-12-31	2005-07-28	Garth Boehm	Alprazolam formulations
US7619007B2 (en) *	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US20060159753A1 (en) *	2004-12-27	2006-07-20	Eisai Co. Ltd.	Matrix type sustained-release preparation containing basic drug or salt thereof

2005
- 2005-12-12 US US11/794,212 patent/US20090208579A1/en not_active Abandoned
- 2005-12-27 EP EP05822550A patent/EP1832298A4/en not_active Withdrawn
- 2005-12-27 WO PCT/JP2005/023853 patent/WO2006070781A1/en not_active Ceased
- 2005-12-27 AU AU2005320609A patent/AU2005320609B9/en not_active Ceased
- 2005-12-27 JP JP2006550780A patent/JP4999466B2/en not_active Expired - Fee Related
- 2005-12-27 NZ NZ555901A patent/NZ555901A/en not_active IP Right Cessation
- 2005-12-27 BR BRPI0519407-5A patent/BRPI0519407A2/en not_active Application Discontinuation
- 2005-12-27 CA CA2592102A patent/CA2592102C/en not_active Expired - Fee Related
- 2005-12-27 KR KR1020077014510A patent/KR100904602B1/en not_active Expired - Lifetime
- 2005-12-27 CN CN201310421659.XA patent/CN103550190A/en active Pending
- 2005-12-27 MX MX2007007835A patent/MX2007007835A/en active IP Right Grant
2007
- 2007-06-12 IL IL183871A patent/IL183871A0/en unknown
- 2007-07-04 NO NO20073461A patent/NO20073461L/en not_active Application Discontinuation
2010
- 2010-10-22 US US12/910,313 patent/US20110045074A1/en not_active Abandoned

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0194838A2 (en) *	1985-03-08	1986-09-17	Yamanouchi Pharmaceutical Co. Ltd.	Controlled-release pharmaceutical formulation
US4968508A (en) *	1987-02-27	1990-11-06	Eli Lilly And Company	Sustained release matrix
JPH06199657A (en) *	1992-12-10	1994-07-19	Sumitomo Pharmaceut Co Ltd	Sustained release formulation
JPH0920663A (en) *	1995-07-07	1997-01-21	Teikoku Seiyaku Co Ltd	Sustained release fine granules containing ibudilast and method for producing the same
WO2000018378A1 (en) *	1998-09-25	2000-04-06	Euro-Celtique, S.A.	Sustained release hydromorphone formulations exhibiting bimodal characteristics
EP1086706A1 (en) *	1999-03-31	2001-03-28	Eisai Co., Ltd.	Stabilized compositions containing nootropic drugs
WO2004087116A2 (en) *	2003-03-05	2004-10-14	Osmotica Corp.	Drug combination for motor dysfunction in parkinson's disease
WO2005092336A1 (en) *	2004-03-26	2005-10-06	Eisai R&D Management Co., Ltd.	Controlled-leaching preparation and process for producing the same
EP1728512A1 (en) *	2004-03-26	2006-12-06	Eisai R&D Management Co., Ltd.	Controlled-leaching preparation and process for producing the same
CN1608623A (en) *	2004-11-05	2005-04-27	贵州圣济堂制药有限公司	Enteric coated donepezil hydrochloride tablet and its perpn process
WO2006070930A1 (en) *	2004-12-27	2006-07-06	Eisai R & D Management Co., Ltd.	Method for stabilizing anti-dementia drug
EP1878444A1 (en) *	2005-04-28	2008-01-16	Eisai R&D Management Co., Ltd.	Composition containing antidementia agent
CN1709229A (en) *	2005-06-10	2005-12-21	北京阜康仁生物制药科技有限公司	Memantine hydrochloride orally disintegrating tablet and its preparing method

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAN, YIDONG ET AL: "Orally disintegrating tablet of memantine hydrochloride, and its preparation method and use", XP002686008, retrieved from STN Database accession no. 2006:1073087 *
DATABASE WPI Section Ch Week 199433, Derwent World Patents Index; Class A96, AN 1994-269350, XP002686005, MIURA M; NISHII H; TOYODA Y: "Sustained release prepn. with release rate independent of acidity - comprising basic drug most soluble in weak acid, enteric base and specified polymer in water-soluble polymer matrix" *
DATABASE WPI Section Ch Week 199713, Derwent World Patents Index; Class B02, AN 1997-140825, XP002686007, FUWA N; KONISHI R; OYAMA H; WATOU T; YAMADA A: "Sustained-release fine particle prepn. contg. ibudilast - has the ibudilast heated with high mol. cpd. and oil/fat base then granulated" *
DATABASE WPI Section Ch Week 200561, Derwent World Patents Index; Class B05, AN 2005-592331, XP002686009, DING L: "Donepezil hydrochloride in the form of an enterically coated tablet, useful for the treatment of senile dementia" *
NAGARSENKER M S; GOVINDARAJAN R: "Solid dispersion for extended release of verapamil HCl", PHARMACY AND PHARMACOLOGY COMMUNICATIONS, vol. 4, no. 7, 1998, pages 331 - 334, XP002686006 *
RAFIEE-TEHRANI M ET AL: "Effect of different polymers on the release characteristics of carbamazepine from stable controlled-release tablets prepared by the air suspension and wet granulation techniques", ACTA PHARMACEUTICA, CROATIAN PHARMACEUTICAL SOCIETY, HR, vol. 50, no. 4, 1 January 2000 (2000-01-01), pages 291 - 301, XP008157580, ISSN: 1330-0075 *
See also references of WO2006070781A1 *
STREUBEL A ET AL: "pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 67, no. 1, 1 June 2000 (2000-06-01), pages 101 - 110, XP004196077, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(00)00200-5 *

Also Published As

Publication number	Publication date
AU2005320609A1 (en)	2006-07-06
NZ555901A (en)	2010-10-29
US20090208579A1 (en)	2009-08-20
EP1832298A1 (en)	2007-09-12
CN103550190A (en)	2014-02-05
AU2005320609B9 (en)	2010-03-18
MX2007007835A (en)	2007-08-20
IL183871A0 (en)	2007-10-31
JP4999466B2 (en)	2012-08-15
CA2592102C (en)	2012-01-24
JPWO2006070781A1 (en)	2008-06-12
NO20073461L (en)	2007-09-27
KR20070089207A (en)	2007-08-30
KR100904602B1 (en)	2009-06-25
CA2592102A1 (en)	2006-07-06
AU2005320609B2 (en)	2009-07-02
WO2006070781A1 (en)	2006-07-06
US20110045074A1 (en)	2011-02-24
BRPI0519407A2 (en)	2009-01-20

Publication	Publication Date	Title
EP1832298A4 (en)	2012-12-12	Matrix-type controlled release preparation comprising basic substance or salt thereof, and process for production of the same
TWI365866B (en)	2012-06-11	Amide derivatives, process for preparation thereof and use thereof as insecticide
IL190137A0 (en)	2008-08-07	Crystals of laquinimod sodium, and process for the manufacture thereof
HUS1400056I1 (en)	2016-08-29	Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
SI1797037T1 (en)	2015-06-30	PROCESS FOR THE PREPARATION OF 4-š4-Š(šŠ4-CHLORO-3-(TRIFLUOROMETHYL)PHENYLĆAMINOćCARBONYL)AMINOĆPHENYOXYćN-METHYLPYRIDINE-2-CARBOXAMIDE
ZA200702382B (en)	2008-08-27	Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
IL189914A0 (en)	2008-08-07	Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them
IL188306A0 (en)	2008-04-13	Crystals of phenylalanine derives,, production method thereof and use thereof
IL179758A (en)	2010-12-30	Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof and use of the same as medicaments
IL184314A0 (en)	2007-10-31	Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
ZA200801896B (en)	2009-09-30	Slow-release composition, method for the preparation thereof, and use of the same
ZA200705119B (en)	2008-06-25	Matrix type sustained-release preparation containing basic drug or salt thereof, and method for manufacturing the same
PT1750700E (en)	2008-01-18	Liquid preparation for veterinary medicine, method for the production thereof, and use of the same
IL176515A0 (en)	2006-10-05	1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
EP1731139A4 (en)	2008-12-03	S/o type pharmaceutical preparation and process for producing the same
SI2020410T1 (en)	2014-04-30	PyridoŠ2,3-dĆpyrimidine derivatives, process for their preparation and their therapeutical use
PL1763508T3 (en)	2011-12-30	Process for the preparation of urea
IL190230A0 (en)	2008-11-03	Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
EP1984327A4 (en)	2010-11-10	An improved process for the preparation of cilastatin and sodium salt
EG23973A (en)	2008-02-24	Process for the preparation of urea ganules
PL1753720T3 (en)	2014-09-30	Process for the preparation of perindopril and salts thereof
ZA200606542B (en)	2008-07-30	1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
HU0401379D0 (en)	2004-09-28	Process for the preparation of risperidon
IL173447A0 (en)	2006-06-11	Substituted benzoylureido-o-benzoylamides, method for the production thereof and use of the same
TWI365874B (en)	2012-06-11	One-pot process for the preparation of 1,2-benz-isoxazole-3-methanesulfonamide

Legal Events

Date	Code	Title	Description
2007-08-10	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2007-09-12	17P	Request for examination filed	Effective date: 20070625
2007-09-12	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2007-09-12	AX	Request for extension of the european patent	Extension state: AL BA HR MK YU
2008-09-05	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1112400 Country of ref document: HK
2012-12-12	A4	Supplementary search report drawn up and despatched	Effective date: 20121113
2012-12-12	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/20 20060101AFI20121105BHEP Ipc: A61P 25/28 20060101ALI20121105BHEP Ipc: A61K 31/445 20060101ALI20121105BHEP Ipc: A61K 31/13 20060101ALI20121105BHEP
2016-01-06	17Q	First examination report despatched	Effective date: 20151203
2016-08-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2016-09-28	18D	Application deemed to be withdrawn	Effective date: 20160414
2017-07-21	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1112400 Country of ref document: HK